14-3-3 γ Activators
14-3-3 γ activators comprise a diverse group of chemical compounds that potentially modulate the activity of the 14-3-3 γ protein. These compounds can exert their effects through various mechanisms, influencing signaling pathways and cellular processes associated with 14-3-3 γ regulation. BV02, a selective activator of protein kinase C (PKC), has the potential to activate 14-3-3 γ by impacting PKC-mediated signaling pathways. PKC plays a crucial role in phosphorylation events, and BV02's action on PKC may lead to modifications in the phosphorylation status of proteins interacting with 14-3-3 γ, thereby affecting downstream cellular processes regulated by 14-3-3 γ. Indirubin-3'-monoxime, known for inhibiting cyclin-dependent kinases (CDKs), is another compound that may activate 14-3-3 γ. By disrupting the cell cycle through CDK inhibition, it can influence the phosphorylation status of proteins involved in 14-3-3 γ signaling pathways, contributing to the modulation of 14-3-3 γ activity and its associated cellular functions.
Go6983, a broad-spectrum PKC inhibitor, and Leptomycin B, a specific inhibitor of CRM1, provide alternative routes for potentially activating 14-3-3 γ. Go6983's inhibition of PKC may indirectly impact 14-3-3 γ, while Leptomycin B's interference with nucleocytoplasmic transport could alter the subcellular localization of proteins interacting with 14-3-3 γ. Compounds such as SP600125, LY294002, Wortmannin, LY303511, Bisindolylmaleimide I, U0126, and SB203580 target specific kinases or pathways connected to 14-3-3 γ signaling. For instance, SP600125 inhibits JNK, LY294002 and Wortmannin inhibit PI3K, and U0126 inhibits MEK. Each of these compounds may indirectly influence 14-3-3 γ activity through shared downstream effectors, contributing to the regulation of cellular processes governed by 14-3-3 γ. In summary, these diverse chemical activators collectively offer valuable tools for investigating the intricate regulatory mechanisms of 14-3-3 γ and its involvement in crucial cellular processes. Understanding the specific biochemical and cellular pathways influenced by these compounds provides insights into the complex interplay of signaling networks controlled by 14-3-3 γ in various physiological contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime, an inhibitor of cyclin-dependent kinases (CDKs), can potentially activate 14-3-3 γ by modulating the cell cycle. By inhibiting CDKs, this compound may disrupt cell cycle progression and influence the phosphorylation status of proteins that interact with 14-3-3 γ, consequently impacting cellular processes where 14-3-3 γ plays a regulatory role. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983, a broad-spectrum inhibitor of protein kinase C (PKC), may indirectly activate 14-3-3 γ by affecting PKC-mediated signaling pathways. Inhibition of PKC by Go6983 could alter the phosphorylation state of proteins interacting with 14-3-3 γ, influencing cellular processes regulated by 14-3-3 γ. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Leptomycin B, a specific inhibitor of CRM1 (exportin-1), can potentially activate 14-3-3 γ by affecting nucleocytoplasmic transport. By inhibiting CRM1, Leptomycin B may alter the subcellular localization of proteins interacting with 14-3-3 γ, influencing the regulatory functions of 14-3-3 γ in various cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), a kinase implicated in 14-3-3 γ signaling pathways. By blocking JNK, SP600125 may indirectly affect 14-3-3 γ activity through shared downstream effectors, potentially modulating cellular processes regulated by 14-3-3 γ. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinase (PI3K), a pathway connected to 14-3-3 γ signaling. By disrupting PI3K, LY294002 may indirectly affect 14-3-3 γ activity through shared downstream effectors, potentially influencing cellular processes regulated by 14-3-3 γ. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a pathway implicated in 14-3-3 γ signaling. By inhibiting PI3K, Wortmannin may indirectly affect 14-3-3 γ activity through shared downstream effectors, potentially modulating cellular processes regulated by 14-3-3 γ. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511 is a structural analog of LY294002 and inhibits phosphoinositide 3-kinase (PI3K), influencing 14-3-3 γ signaling. By disrupting PI3K, LY303511 may indirectly affect 14-3-3 γ activity through shared downstream effectors, potentially modulating cellular processes regulated by 14-3-3 γ. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a pan-protein kinase C (PKC) inhibitor, which may indirectly activate 14-3-3 γ by influencing PKC-mediated signaling pathways. Inhibition of PKC by Bisindolylmaleimide I could alter the phosphorylation state of proteins interacting with 14-3-3 γ, influencing cellular processes regulated by 14-3-3 γ. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 mitogen-activated protein kinase (MAPK), a pathway implicated in 14-3-3 γ signaling. By blocking p38 MAPK, SB203580 may indirectly influence 14-3-3 γ activity through shared downstream effectors, potentially modulating cellular processes regulated by 14-3-3 γ. | ||||||